Skip to main content

Diabetic Kidney Disease News

Empagliflozin Has Kidney Protective Effects in Acute Myocardial Infarction

THURSDAY, June 26, 2025 – Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI),...

1990 to 2021 Saw Increase in Global Burden of Diabetic Nephropathy

MONDAY, March 17, 2025 – The global burden of diabetic nephropathy increased from 1990 to 2021, and is projected to continue increasing to 2050, according to a study published online Feb. 21 in...

FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD

RARITAN, N.J., Sept. 30, 2019 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

lisinopril, losartan, ramipril, Invokana